TAO Synergies (TAOX) EBITDA Margin (2025 - 2026)
TAO Synergies' (TAOX) quarterly EBITDA Margin came in at 1770.63% in Q2 2026, up 7485312.0% on a YoY basis from N/an in Q2 2025, and down 422.38% quarter-over-quarter from 338.95% in Q1 2026.
Powered by 
Analysis
TAO Synergies (TAOX) EBITDA Margin (2025 - 2026) Analysis & Trends
TAO Synergies (TAOX) has reported EBITDA Margin for 2 consecutive years, with 1770.63% the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, EBITDA Margin rose 7485312.0% year-over-year to 1770.63%; the trailing twelve-month figure through Jun 2026 stood at 1013.48% (changed N/A YoY), and the FY2025 full-year result was 3025.19%, changed N/A from the prior year.
- EBITDA Margin declined to 1770.63% in Q2 2026 per TAOX's latest filing, from 338.95% in the prior quarter.
- Across five years, EBITDA Margin topped out at 338.95% in Q1 2026 and bottomed at 76623.75% in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.50 Bn | 197.51 Bn | 7.24 Bn | 34.95% |
| 2 | Gilead Sciences | 181.29 Bn | 178.11 Bn | 6.22 Bn | -133.21% |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 37.40% |
| 4 | Regeneron Pharmaceuticals | 82.55 Bn | 74.56 Bn | 3.93 Bn | 30.15% |
| 5 | Argenx Se | 61.65 Bn | 56.47 Bn | 1.37 Bn | 32.54% |
| 6 | Moderna | 54.65 Bn | 49.52 Bn | 52.00 Mn | -562.07% |
| 7 | Alnylam Pharmaceuticals | 34.18 Bn | 30.87 Bn | 992.69 Mn | 17.93% |
| 8 | Biogen | 31.36 Bn | 30.07 Bn | 1.96 Bn | -23.56% |
| 9 | Roivant Sciences | 30.01 Bn | 30.01 Bn | 1.16 Mn | -25,380.93% |
| 10 | TAO Synergies | 30.79 Mn | 30.79 Mn | - | -1,770.63% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1,770.63% |
| Mar 31, 2026 | -338.95% |
| Dec 31, 2025 | -3,426.06% |
| Sep 30, 2025 | -884.84% |
| Jun 30, 2025 | -76,623.75% |